Bristol Myers Squibb plans to build a $2.3 billion manufacturing campus in Houston — a major expansion of U.S. drug production as the industry brings more manufacturing home.
Announced August 10, 2026, the campus in Houston’s Generation Park will produce multiple types of medicines: small molecules, biologics, antibody-drug conjugates (ADCs), and finished drug products from late development through launch. It is part of BMS’s broader $40 billion five-year U.S. investment commitment.
Jobs and timeline
BMS expects about 500 permanent skilled jobs at the site, plus roughly 2,000 construction and indirect jobs during a build-out running from 2027 to 2030. The company cited Houston’s growing life-sciences workforce, infrastructure and business climate; Texas is contributing incentives, including a $4.89 million Texas Enterprise Fund grant.
The bigger picture
The investment fits a wave of pharma companies expanding U.S. manufacturing, driven partly by policy: new 100% tariffs on some foreign-made treatments took effect July 31, 2026, sharpening the case for domestic production. “This investment reflects our confidence in America’s continued leadership in biopharmaceutical innovation,” said BMS CEO Christopher Boerner. For patients, more onshore capacity can mean a more resilient drug supply.